Stelara
E50227
Stelara is a prescription biologic medication (ustekinumab) used to treat autoimmune conditions such as psoriasis, psoriatic arthritis, and Crohn’s disease by targeting specific immune system pathways.
Statements (49)
| Predicate | Object |
|---|---|
| instanceOf |
biologic medication
→
monoclonal antibody → prescription drug → |
| hasATCCode |
L04AC05
→
|
| hasCommonSideEffect |
fatigue
→
headache → injection site reactions → upper respiratory infections → |
| hasDosingFrequency |
every 8 weeks (maintenance, common regimen)
→
|
| hasDrugClass |
interleukin inhibitor
→
|
| hasGenericName |
ustekinumab
→
|
| hasInitialDosing |
weight-based intravenous induction for Crohn’s disease
→
weight-based intravenous induction for ulcerative colitis → |
| hasMaintenanceDosing |
subcutaneous injection
→
|
| hasMolecularType |
human monoclonal antibody
→
|
| hasPediatricIndicationFor |
plaque psoriasis
→
psoriatic arthritis → |
| hasRouteOfAdministration |
intravenous infusion
→
subcutaneous injection → |
| hasSeriousRisk |
hypersensitivity reactions
→
malignancies → serious infections → |
| hasTargetDiseaseArea |
dermatology
→
gastroenterology → rheumatology → |
| isAdministered |
parenterally
→
|
| isAdministeredBy |
healthcare professional
→
|
| isApprovedBy |
European Medicines Agency
→
U.S. Food and Drug Administration → |
| isContraindicatedIn |
patients with clinically significant hypersensitivity to ustekinumab
→
|
| isIndicatedIn |
adults
→
pediatric patients → |
| isManufacturedBy |
Janssen Biotech
→
|
| isMarketedBy |
Janssen
→
|
| isUsedFor |
Crohn’s disease
→
active psoriatic arthritis → moderate to severe plaque psoriasis → moderately to severely active Crohn’s disease → moderately to severely active ulcerative colitis → plaque psoriasis → psoriatic arthritis → ulcerative colitis → |
| mechanismOfAction |
binds to p40 subunit of IL-12 and IL-23
→
blocks IL-12 and IL-23 mediated signaling → |
| reduces |
inflammation
→
|
| regulates |
immune system response
→
|
| requiresMonitoringFor |
signs of infection
→
|
| targets |
interleukin-12
→
interleukin-23 → |
Referenced by (1)
| Subject (surface form when different) | Predicate |
|---|---|
|
Johnson & Johnson
→
|
notableProduct |